NanoSanguis

What NanoSanguis does

NanoSanguis S.A. is a Polish biotechnology company headquartered in Warsaw, operating as a wholly-owned subsidiary (spółka zależna) of the publicly-listed NanoGroup S.A. (Warsaw Stock Exchange). Founded by a research team from Politechnika Warszawska (Warsaw University of Technology), the company develops nanotechnology-based solutions for two distinct clinical problems: organ preservation in transplantology and blood substitution in transfusion medicine. Its core platform, the NanOX system, uses perfluorocarbon nanoparticles that mimic red blood cell functions — transporting oxygen and removing carbon dioxide under sub- and normothermic conditions. This enables extended ischemia tolerance (30-40 minutes versus a few minutes in traditional methods), supporting the use of marginal donor organs including kidneys from donors after circulatory death (DCD). The product portfolio comprises the NanOX System, the lead asset NanOX 4 Kidney (a next-generation kidney perfusion solution), the OrganFarm long-term ex vivo organ storage system (project completed), and a parallel Red Blood Cell Substitute program. Customer segments are pre-commercial and aimed at transplant centers and blood banks; the company has no marketed products and is funded almost exclusively through Polish and EU non-dilutive grants totaling over 25.6 million PLN in cumulative project value.

The company's business model is currently grant-funded R&D rather than revenue-generating commercialization, with no disclosed pricing, no commercial sales, and no paying customers. Strategic direction is provided by a small team (1-10 employees) with a senior supervisory board drawn from the Polish pharmaceutical industry (former executives of AstraZeneca, Pfizer, MSD, PZU, IQVIA). Capital structure is lean — paid-in share capital of approximately 4.07 million PLN — with operating capital supplied through mechanisms such as the Polish Medical Research Agency (ABM), the National Centre for Research and Development (NCBiR), EU structural funds, and the FENG 2021-2027 program. The NanOX 4 Kidney program (FENG.01.01-IP.02-1136/24) is the most advanced lead indication and is positioned as the primary value-creating asset, while parallel programs in oncology (ABM/KPO dextran conjugate, 2024) and CNS infectious disease (ENM3/V/33/Antineuropatho/2023, EuroNanoMed III) demonstrate platform extensibility but also dilute near-term focus.

Name

NanoSanguis

Legal name

NanoSanguis S.A.

Website

https://nanosanguis.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

NanoSanguis is a pre-revenue Warsaw-based biotech subsidiary of NanoGroup S.A. that develops perfluorocarbon-nanoparticle (NanOX) perfusion fluids and organ storage systems to extend donor organ viability for transplantology, with a parallel red blood cell substitute program for transfusion medicine.

Ownership category

akta.pro rank

Product category

Organ Perfusion and Preservation Biotechnology

NAICS

Research and Development in Nanotechnology (541713), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)

akta.pro secondary industry

Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ)

Keywords

• Organ perfusion technology
• Synthetic blood substitute
• Nanoparticle oxygen carriers
• Transplant medicine biotech
• Ex vivo organ storage

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

NanoSanguis develops nanotechnology-based perfusion fluids and organ storage systems (the NanOX platform, including NanOX 4 Kidney, and the OrganFarm system) that extend donor organ viability for transplantation. The company also pursues a synthetic Red Blood Cell Substitute for transfusion medicine. All offerings are at preclinical/R&D stage and are intended for transplant centers, hospitals, and blood banks.

Product overview

NanoSanguis is a biotechnology company developing a portfolio of nanotechnology-based medical products for transplantology and transfusiology. The core technology centers on perfluorocarbon nanoparticle-based perfusates, including the NanOX System (NanOX 4 Kidney), which provides advanced organ preservation by mimicking natural blood functions. The company also developed the OrganFarm system for long-term ex vivo organ storage. These products work together as an integrated solution: NanOX delivers oxygen to organs during preservation, extending ischemia tolerance from minutes to 30-40 minutes, while OrganFarm enables extended storage. The company is also developing a synthetic blood substitute (Red Blood Cell Substitute) as a parallel product line for transfusiology applications.

Differentiator

Problem solved

Functional benefit

Brands

• NanOX: Nanoparticle-based perfusion system for organ storage and regeneration. Uses perfluorocarbon nanoparticles that mimic red blood cell functions, transporting oxygen and removing carbon dioxide in sub- and normothermic conditions.
• NanOX 4 Kidney
• OrganFarm

Products and services

• NanOX System Advanced organ perfusion and regeneration system based on perfluorocarbon nanoparticle technology operating under sub- and normothermic conditions. The system transports oxygen and removes carbon dioxide in a manner similar to natural human blood, extending ischemia tolerance and supporting organ metabolism and regeneration during preservation. Targeted at transplant centers and hospitals performing organ transplant procedures.
• NanOX 4 Kidney Next-generation kidney perfusion solution based on synthetic oxygen carrier perfluorocarbon nanoparticles, designed to extend the viable preservation window for kidneys (in particular from DCD donors) and to enable broader use of marginal donor organs. Targeted at transplant centers performing kidney transplantation.
• OrganFarm System for long-term ex vivo organ storage intended to establish a new standard in transplantology by extending organ viability beyond traditional preservation methods. Targeted at transplant centers and organ procurement organizations.
• Red Blood Cell Substitute (Substytut Czerwonych Krwinek) Synthetic blood substitute program using perfluorocarbon nanoparticles to mimic red blood cell functions for oxygen transport and carbon dioxide removal, intended to address short shelf life and supply constraints of donated blood. Targeted at blood banks and transfusion medicine institutions.

Quantifiable outcome

• 164 people die daily waiting for kidney transplants worldwide
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• NanoGroup S.A.coreOthersNanoSanguis is a subsidiary company of NanoGroup S.A. The parent company provides strategic direction and is listed on the Warsaw Stock Exchange. NanoGroup SA focuses on nanotechnology applications in medicine and owns the NanoSanguis subsidiary.
• Politechnika Warszawska (Warsaw University of Technology)coreStrategic or Co-development PartnerNanoSanguis was founded by a team of scientists from the Warsaw University of Technology. The academic institution provides research expertise and scientific foundation for the company's nanobiotechnology developments in organ perfusion and blood substitutes.
• European Consortium (for ENM3/V/33/Antineuropatho/2023)minorStrategic or Co-development PartnerEuropean research consortium for the 'Developing novel nanopharmaceutics against bacterial infections at center nervous system' project. NanoSanguis participates in this transnational collaborative research initiative.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nanosanguis-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanoSanguis